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Non-dextran intravenous (i.v.) iron preparations seem to
differentially affect proteinuria in patients with chronic
kidney disease. To study effects of ferric gluconate and iron
sucrose on proteinuria, we conducted a crossover trial in
12 patients with stage 3–4 chronic kidney disease. These
patients were randomized to receive the same dose of either
drug 1 week apart. Urine samples were obtained immediately
before and at frequent intervals after the drug. The urine
total protein/creatinine ratio was significantly greater after
iron sucrose than ferric gluconate treatment with the effect
noted within 15 min post-infusion. Furthermore, when iron
sucrose was given first, a significantly greater protein/
creatinine ratio was seen subsequently with ferric gluconate
than with the reverse order of treatment. The urine albumin/
creatinine ratio was also significantly greater with iron
sucrose than with ferric gluconate. There was no significant
difference, however, between the two i.v. irons in the
measured urine N-acetyl-b-D-glucosaminidase/creatinine
ratio. Although our study showed that acutely, iron sucrose
increased proteinuria, the long-term effects of repeated i.v.
non-dextran iron on kidney function requires further study.
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Anemia of chronic kidney disease (CKD) is frequently
complicated by iron deficiency. Iron deficiency in patients
with CKD not on hemodialysis may be treated using
either oral or intravenous (i.v.) iron.1,2 However the i.v.
route is being frequently utilized. Although the i.v. route
offers some advantages including improved adherence to
treatment3 and improved quality of life,4 the long-term
risk of oral compared to i.v. iron have not been studied.
Owing to their more favorable short-term side effect
profile,5,6 non-dextran i.v. iron preparations, that is, ferric
gluconate and iron sucrose, have largely replaced iron
dextrans for use in practice in the United States. However,
the long-term side effects of these newer preparations
includes the potential for causing nephrotoxicity in clinically
relevant concentrations.7 Studies in animals and human
proximal tubular kidney cells in culture have shown
nephrotoxicity both due to iron sucrose and ferric gluconate
with a strong signal for differential toxicity.7 In fact,
experiments in patients with CKD also demonstrate that
these drugs may have differential toxicity. While iron
sucrose was associated with greater proteinuria, ferric
gluconate was not.8,9 These are clinically important outcomes
and generate the hypothesis that appearance of proteinuria
may be linked to accelerated progression to end stage renal
disease. If i.v. iron can directly worsen proteinuria, its
frequent administration to CKD patients, and even perito-
neal dialysis patients, may have dire consequences in the long
term. Nevertheless, clinicians may often encounter situations
when i.v. iron therapy is the best treatment option, in which
case they may wish to use the preparation that results in
less proteinuria. Unfortunately, there are no randomized
controlled trials comparing ferric gluconate to iron sucrose
head-to-head.
Since there was plausible evidence suggesting that the two
available non-dextran i.v. iron preparations may have
different effects on the kidney and on proteinuria,8,9 we
conducted a randomized, controlled, crossover study to
compare their effects on proteinuria. The primary objective
of this study was to compare the difference between the ferric
gluconate and iron sucrose in terms of change in urine total
protein to creatinine ratio. Secondary objectives were to
compare the two drugs in terms of change in urine albumin
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to creatinine ratio and change in urine N-acetyl-b-
D-glucosaminidase (NAG) to creatinine ratio.
RESULTS
Thirteen patients were randomized into this two-period
crossover trial as outlined in Figure 1 and discussed in
Methods (see below). One patient, who was randomized to
received iron sucrose in dosing phase A and ferric gluconate
in dosing phase B, was withdrawn from the study a day after
receiving iron sucrose due to hospitalization for a urinary
tract infection caused by Klebsiella and Escherichia coli.
Therefore, 12 patients completed the study and were included
in the statistical analysis.
Table 1 summarizes the baseline characteristics of the 12
patients who completed the trial, which represents the
population of CKD patients, except that there are more
women in our sample.
Figure 2 shows the least-square mean change from pre-
infusion urine total protein/creatinine ratio for each drug.
Overall, iron sucrose resulted in greater urine total protein/
creatinine ratio than ferric gluconate (Po0.001). On average
pre-infusion urine total protein/creatinine ratio were 1.32
(s.d. 2.71) g/g creatinine with ferric gluconate and 1.23 (s.d.
2.53) g/g creatinine with iron sucrose (P¼ 0.132). At 180 min
post-infusion, urine total protein/creatinine ratios were
1.69 (s.d. 3.20) g/g creatinine and 2.28 (s.d. 3.53) g/g
creatinine with ferric gluconate and iron sucrose, respectively
(P¼ 0.002). As shown in Figure 2, iron sucrose resulted in
greater total protein excretion in the urine as early as 15 min
post-infusion.
As with all crossover studies, we investigated if the
difference between the two i.v. iron preparations in
proteinuria response was dependent on the order in which
the drugs are given. We found that when ferric gluconate was
given at dosing phase A, the difference between the two i.v.
iron preparations was larger than when iron sucrose was
given at dosing phase A (Po0.01). As shown in Figure 3,
ferric gluconate resulted in more proteinuria when it was
preceded by iron sucrose (solid line) than when it was given
first (dashed line), which resulted in this significant period
effect (Po0.01). Regardless of this phenomenon, iron
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Figure 1 | A schematic of study procedures.
Table 1 | Baseline characteristics of study completersa
N 12
Age (years) 67.3711.3
Females (n (%)) 9 (75.0)
Weight (kg) 85.2719.8
Height (cm) 162.6710.4





Estimated glomerular filtration rate (ml/min/1.73 m2) 29.0711.2




White blood cells (1000/mcL) 6.671.7
Mean corpuscular volume (mcm3) 92.176.6
Mean corpuscular hemoglobin (pg/cell) 29.972.5
Blood urea nitrogen (mg/dl) 44.7716.4
Serum creatinine (mg/dl) 2.271.2
Serum albumin (g/dl) 4.270.4
C-reactive protein (mg/l) 5.475.6
Serum ferritin (ng/ml) 1577134
Transferrin saturation (%) 23.4710.0
Patients on ACE inhibitors or ARBs (n (%)) 8 (67%)
ACE, angiotensin converting enzyme, ARB, angiotensin receptor blocker.
aContinuous variables are presented in the form of mean7s.d.
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gluconate. The mean baseline urine data before the first and
second infusion were similar.
Figure 4 shows the change from pre-infusion urine
albumin/creatinine ratio. Overall, iron sucrose resulted in
greater albumin excretion in the urine than ferric gluconate
(Po0.001). Pre-infusion log urine albumin/creatinine ratios
were similar with the two i.v. iron preparations; 0.91 (s.d. 2.0)
g/g creatinine with ferric gluconate and 0.97 (s.d. 2.1) g/g
creatinine with iron sucrose (P¼ 0.730). By 180 min, iron
sucrose had resulted in greater log urine albumin/creatinine
ratio (1.9 (s.d. 3.1) g/g creatinine) than ferric gluconate
(1.3 (s.d. 2.5) g/g creatinine) (P¼ 0.002). This trend was also
statistically significant at the 30 min assessment point.
As for urine NAG/creatinine ratio, there was no statisti-
cally significant difference between the two i.v. iron
preparations at any of the assessment points or overall
(P¼ 0.91). Pre-infusion urine NAG/creatinine ratios were 6.9
(s.d. 3.4) U/g creatinine and 8.9 (s.d. 6.0) U/g creatinine with
ferric gluconate and iron sucrose, respectively (P¼ 0.22). At
the 180 min assessment point, the urine NAG/creatinine
ratios were 10.9 (s.d. 7.8) U/g creatinine with ferric gluconate
and 20.0 (s.d. 17.1) U/g creatinine with iron sucrose (overall
P¼ 0.91). Although there were no differences between the i.v.
irons in the NAG/creatinine ratio, the mean change in NAG/
creatinine ratio after iron infusion was 5.88 U/g (95%
confidence interval 1.11–10.65), P ¼ 0.021. Thus, both i.v.
irons increased enzymuria over baseline.
We analyzed whether angiotensin converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB) use
was associated with change in albuminuria in response to i.v.
iron injection. Pre-infusion level of albuminuria were similar
in those using ACE inhibitors or ARBs compared to those not
on those agents. Those patients not on the drug experienced
greater albuminuria when exposed to iron sucrose (455 mg/g
for iron sucrose, 138 mg/g for iron gluconate); albuminuria
was similar when exposed to iron sucrose or iron gluconate
when patients were on ACE inhibitors or ARBs (133 mg/g for
iron sucrose and 143 mg/g for iron gluconate) (P¼ 0.0006 for
ACE/ARB treatment group interaction). Similar ACE/
ARB treatment group interaction (P¼ 0.0003) was seen
in case of protein/creatinine ratio, but no effect (P40.20)
was seen for NAG/creatinine ratio. The level of estimated
glomerular filtration rate (o30 (n¼ 8) or 430 ml/min/
1.73 m2 (n¼ 4)) did not influence albuminuria, proteinuria,
or enzymuria responses.
From a safety perspective, except for the patient who was
hospitalized for urinary tract infection a day after receiving
iron sucrose and removed from the study, none of the
participants experienced any adverse events.
DISCUSSION
The major finding that emerged from this crossover
randomized, controlled trial was that iron sucrose resulted
in much greater protein excretion rate compared to iron





























Figure 2 | Change in least-square mean urine total protein/
creatinine ratio. Iron sucrose is represented by the solid line (—) and
ferric gluconate is represented by the dashed line (– – –). The asterisks
(*) denote assessment points were difference between the two
treatments is statistically significant (Po0.05). Significantly greater
total protein was excreted in the urine with iron sucrose as early as
15 min post-infusion. Overall, iron sucrose resulted in greater
























Figure 3 | An illustration of the effect of administration sequence
of i.v. iron preparations on the geometric mean of overall change
in urine total protein to creatinine ratio from the pre-infusion
period. When ferric gluconate is administered first (– – –), the
difference between the two treatments is larger than when iron


























Figure 4 | Change in least-square mean urine albumin (Alb)/
creatinine (Cr) ratio. Iron sucrose is represented by the solid line (—)
and ferric gluconate is represented by the dashed line (– – –).
The asterisks (*) denote assessment points were difference between
the two treatments is statistically significant (Po0.05). Significantly
greater albumin was excreted in the urine with iron sucrose as early
as 30 min post-infusion. Overall, iron sucrose resulted in greater
excretion of albumin in the urine than ferric gluconate (Po0.001).
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confirmed by albumin/creatine ratio. There was no clinical
difference seen for enzymuria. Furthermore, iron sucrose
administration conditioned the kidney 1 week later to
experience greater injury in response to ferric gluconate than
when ferric gluconate was administered first.
Although albuminuria is generally considered a better
marker of renal injury compared to proteinuria, we selected
proteinuria as the primary end point because previous studies
have demonstrated that administration of i.v. iron may injure
the albumin molecule itself.10 These studies have demon-
strated that the albumin molecule is carbonylated, fragmented
and loses immunoreactivity in a time-dependent manner
upon administration of i.v. iron. We selected protein/
creatinine ratio rather than protein excretion rate as an end
point because there is less variability in protein/creatinine ratio
compared to protein excretion rate.11 The greater variability in
protein excretion rate from 1 h to the next is presumably due
to problems with incomplete bladder emptying.
Zager et al. have shown that iron sucrose induces greater
cytotoxic effects than ferric gluconate on kidney cells both
in vitro12 and in vivo,7 at suprapharmacologic concentrations12
and at clinically relevant concentrations.7 They suggested that
greater oxidative injury directed specifically at the mitochon-
dria may be the likely mechanism of such damage.7
Furthermore, they concluded that although the clinical
relevance of their findings is not known, caution is warranted
when administering these i.v. iron preparations, especially to
patients with CKD in whom nephrotoxicity is of greater
significance compared to those with normal kidney function or
those who are already on dialysis.7
Our study confirms and extends the previous observations
in patients with CKD. Agarwal et al.8 showed that 100 mg
iron sucrose infusion in CKD patients results in renal tubular
and glomerular damage as measured by increased proteinuria
and enzymuria, which are not attenuated by the administra-
tion of the antioxidant N-acetylcysteine. The resulting
damage resolved within 24 h, but the authors raised
important concerns about the effect of repeated administra-
tion of iron sucrose and long-term effects on the kidneys.
Leehey et al.9 used ferric gluconate at two dosage levels (125
and 250 mg) in patients with CKD and found that although
ferric gluconate caused oxidative stress, there was no evidence
of acute renal injury.
Taken all together, the in vitro,12 in vivo,7 and clinical
evidence8,9 suggested that iron sucrose may result in greater
acute renal injury than ferric gluconate. However, until now,
it was difficult to conclusively make this judgment without
having studied the effects of both i.v. iron preparations under
the same conditions in a randomized, controlled trial. This
randomized, controlled, crossover study strongly suggests
that the two drugs may have different effects on kidney
injury. While it may be that iron sucrose has more ‘toxicity’
as assessed by proteinuria and albuminuria, both of the iron
preparations may exert acute tubular damage, as assessed by
increased NAG excretion. These results are supported by the
animal studies done by Zager et al.7 in which they
demonstrate by electron microscopy that iron sucrose
preferentially accumulates in mesangial cells and podocytes
compared to iron gluconate. However, both drugs cause
some degree of tubular injury in cell cultures.12 We did not
study the mechanism of proteinuria, but it may relate to
acute hemodynamic effect on the glomerular circulation or
transient cytokine-induced proteinuria. Although, effects of
i.v. iron on renal hemodynamics have not been studied, iron
sucrose is known to increase blood and urine cytokine
concentrations in patients with CKD and this may mediate
the proteinuria.13 On the other hand, hemodynamic effects
may play a role. Indeed, in ACE inhibitor/ARB-treated
patients, the effect of i.v. iron sucrose was abrogated.
There are some limitations to our study. We did not study
repeated administrations of i.v. iron, which is more
commonly done in clinical practice. Furthermore, the long-
term impact of repeated administrations of i.v. iron on renal
function was not studied so we cannot comment on the long-
term significance of our findings.
In conclusion, greater protein and albumin excretion
induced by iron sucrose suggests potential for harm in the
long term on renal function in CKD patients. The
conditioning effect of iron sucrose predisposing the kidney
to renal injury and the long-term impact of i.v. iron on renal
function needs further evaluation.
MATERIALS AND METHODS
Eligible patients were at least 18 years old with estimated glomerular
filtration rate p60 ml/min/1.73 m2 (using the simplified modifica-
tion of diet in renal disease equation14) who were not on dialysis and
not expected to initiate dialysis for at least 6 months. They had to
have either transferrin saturationo25% or serum ferritino200 ng/ml,
and hemoglobin p12.5 g/dl. The exclusion criteria were known
hypersensitivity to either study drug, history of multiple drug
allergies, history of renal transplant, receiving immunosuppressive
therapy, use of an investigational drug within 1 month before study,
history of uncontrolled asthma, human immunodeficiency virus,
cancer within last 3 years, rheumatoid arthritis, alcoholism or liver
disease, hemoglobin o8 g/dl, positive urine pregnancy test or
breastfeeding, prior history of i.v. iron administration within
1 month of the study, serum ferritin 4800 ng/ml or transferrin
saturation 450%, anemia due to any cause other than iron
deficiency in non-dialysis CKD, any surgery within 1 month,
systemic or urinary tract infection within 1 month, serum albumin
o3.0 g/dl, serum sodium o130 mEq/l, symptomatic benign pro-
static hyperplasia or any other bladder obstruction condition that, in
opinion of the investigator, would not allow for good urine output.
This study was reviewed and approved by the Institutional
Review Boards of the participating clinical sites before enrollment
of any participant and was conducted in accordance with the
Declaration of Helsinki. It was registered with the National Insti-
tutes of Health through the National Library of Medicine at www.
clinicaltrials.gov. Study participants provided informed consent
before undergoing any study procedures.
Figure 1 depicts the study procedures. Using a computer-
generated randomization code, patients were randomized centrally
to receive either ferric gluconate (Ferrlecits, Watson Laboratories,
Inc., Morristown, NJ, USA) 100 mg i.v. at dosing phase A followed
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by iron sucrose (Venofers, American Regent Laboratories, Inc.,
Shirley, NY, USA) 100 mg i.v. at dosing phase B, or iron sucrose
100 mg i.v. at dosing phase A followed by ferric gluconate 100 mg i.v.
at dosing phase B.
At dosing phase A (study day 1), blood samples were obtained for
complete blood count and serum chemistry assessments were carried
out before infusion of the iron preparation. Patients drank a volume
of water equivalent to 15 ml/kg of total body weight to ensure water
diuresis. Immediately after providing a pre-infusion urine sample,
patients were administered 100 mg of the i.v. iron preparation
assigned for dosing phase A over 10 min. Post-infusion urine samples
were obtained at 15, 30, 60, 120, and 180 min after the end of the i.v.
iron infusion. At each assessment point, patients emptied their
bladders in a clean container and a sample of that urine was labeled
with the time it was obtained. To ensure good urine output needed
to obtain the next urine sample, patients drank a volume of water
equivalent to the urine volume they had just voided.
Patients retuned 7 days later (study day 8) to undergo phase B
study procedures. Dosing phase B procedures were identical to those
of phase A, except that patients received 100 mg of the other i.v. iron
preparation over 10 min.
All urine samples were analyzed for their concentrations of total
protein, albumin, NAG, and creatinine. Each sample’s total protein/
creatinine concentration ratio, albumin/creatinine concentration
ratio and NAG/creatinine concentration ratio were calculated and
analyzed to avoid any dilution effect. All urine samples were
analyzed at the same central laboratory facility. Urine total protein,
urine creatinine, and urine NAG concentrations were obtained using
colorimetric methodologies and were determined on an Olympus
5400 series analyzer (Olympus Diagnostics, Dallas, TX, USA). Urine
albumin concentrations were obtained by an immunoturbinimetric
methodology using the Roche Cobas Integra analyzer (Roche
Diagnostics, Indianapolis, IN, USA).
Statistical analyses
Sample size estimates were not performed since this was a pilot study.
The primary outcome end point was the change from pre-infusion to
each post-infusion time point (15, 30, 60, 120, and 180 min), for each
treatment period, for total urine protein concentration/urine
creatinine concentration. The secondary outcome end points were
albumin/creatinine concentration ratio and NAG/creatinine concen-
tration ratio. Each of these outcome end points was analyzed using a
mixed models analysis of variance (Proc Mixed in SASs). The model
included terms for sequence, patient within sequence, period, study
drug, post-infusion time point, and study drug-by-post-infusion time
point interaction. Patient was treated as a random effect and all other
factors were treated as fixed effects. In mathematical terms, the model
can be expressed as follows:
Yijklm ¼ Mean þ Si þ PðSÞjðiÞþRk þ Il þ TmþITlm þ errorijklm
where, Si represents the Sequence effect; P(S)j(i) represents the
patient within sequence effect; Rk represents the period effect;
Il represents the study drug effect; Tm represents the post-infusion
time points; ITlm represents the study drug by time point
interaction.
It was determined that the distribution of the random error
associated with each outcome variable did not follow a normal
distribution. As a consequence, all outcome end points were
analyzed after performing a log transformation.
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